靶向治疗后前列腺磁共振评估跨大西洋推荐(TARGET):系统综述与国际共识推荐
该共识基于73项研究的系统综述和两轮RAND/UCLA共识流程(23名来自欧洲和北美的泌尿外科、放射科和病理科专家,覆盖8种局灶治疗模式),提出局灶治疗后前列腺MRI的采集、解读和报告推荐。关键推荐包括在12个月时使用符合PI-RADS v2.1标准的多参数方案进行常规MRI,避免使用PI-RADS分类评分评估消融区内复发,并采用包含DCE序列和DWI联合T2W序列的5点评分系统。
要点
- 推荐在局灶治疗后12个月使用符合PI-RADS v2.1标准的多参数MRI方案进行常规评估。
- 评估消融区内复发时应避免使用PI-RADS分类评分,改用包含DCE和DWI联合T2W的5点评分系统。
- DCE序列上局灶结节状明显早期强化是最可疑的复发影像征象。
核心结论
- TARGET共识推荐可能改善局灶治疗后前列腺MRI的采集、解读和报告,并为研究报道提供最低标准。
研究设计与样本
- 系统综述于2022年7月进行,纳入73项研究;随后进行两轮共识流程(2023年1月共识会议),23名来自欧洲和北美的泌尿外科、放射科和病理科专家对329条陈述进行评分,采用RAND/UCLA方法。
关键影像表现/征象
- 全部20项(100%)报告可疑影像特征的研究均将局灶对比强化列为可疑癌症复发征象。
- 在31项报告MRI评估标准的研究中,PI-RADS评分是最常用的方案(20项研究;65%),其次是5点Likert评分(6项研究;19%)。
- DCE序列上,局灶结节状明显早期强化是最可疑的影像表现。
诊断标准与关键数值
- 推荐在12个月时进行常规MRI,采用符合PI-RADS v2.1标准的多参数方案。
- 评估消融区内复发时应避免使用PI-RADS分类评分。
- 提出替代5点评分系统,包含主要DCE序列和联合次要DWI与T2W序列。
临床应用与阅片要点
- 局灶治疗后随访MRI应按照PI-RADS v2.1标准的多参数方案在12个月时进行。
- 报告消融区内复发时避免使用PI-RADS分类评分,改用包含DCE和DWI联合T2W的5点评分系统。
- 阅片时关注DCE序列上的局灶结节状明显早期强化,视为最可疑的复发征象。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND OBJECTIVE: Magnetic resonance imaging (MRI) can detect recurrences after focal therapy for prostate cancer but there is no robust guidance regarding its use. Our objective was to produce consensus recommendations on MRI acquisition, interpretation, and reporting after focal therapy.
METHODS: A systematic review was performed in July 2022 to develop consensus statements. A two-round consensus exercise was then performed, with a consensus meeting in January 2023, during which 329 statements were scored by 23 panellists from Europe and North America spanning urology, radiology, and pathology with experience across eight focal therapy modalities. Using RAND Corporation/University of California-Los Angeles methodology, the Transatlantic Recommendations for Prostate Gland Evaluation with MRI after Focal Therapy (TARGET) were based on consensus for statements scored with agreement or disagreement.
KEY FINDINGS AND LIMITATIONS: In total, 73 studies were included in the review. All 20 studies (100%) reporting suspicious imaging features cited focal contrast enhancement as suspicious for cancer recurrence. Of 31 studies reporting MRI assessment criteria, the Prostate Imaging-Reporting and Data System (PI-RADS) score was the scheme used most often (20 studies; 65%), followed by a 5-point Likert score (six studies; 19%). For the consensus exercise, consensus for statements scored with agreement or disagreement increased from 227 of 295 statements (76.9%) in round one to 270 of 329 statements (82.1%) in round two. Key recommendations include performing routine MRI at 12 mo using a multiparametric protocol compliant with PI-RADS version 2.1 standards. PI-RADS category scores for assessing recurrence within the ablation zone should be avoided. An alternative 5-point scoring system is presented that includes a major dynamic contrast enhancement (DCE) sequence and joint minor diffusion-weighted imaging and T2-weighted sequences. For the DCE sequence, focal nodular strong early enhancement was the most suspicious imaging finding. A structured minimum reporting data set and minimum reporting standards for studies detailing MRI data after focal therapy are presented.
CONCLUSIONS AND CLINICAL IMPLICATIONS: The TARGET consensus recommendations may improve MRI acquisition, interpretation, and reporting after focal therapy for prostate cancer and provide minimum standards for study reporting.
PATIENT SUMMARY: Magnetic resonance imaging (MRI) scans can detect recurrent of prostate cancer after focal treatments, but there is a lack of guidance on MRI use for this purpose. We report new expert recommendations that may improve practice.
引用
- Light A, Mayor N, Cullen E, et al. The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations. Eur Urol. 2024. PMID: 38519280. doi:10.1016/j.eururo.2024.02.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。